AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

AstraZeneca (AZN) on Monday said that its investigational drug Baxdrostat reduced systolic blood pressure (SBP) compared with ...

AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

AstraZeneca Plc’s experimental hypertension drug Baxdrostat reduced the blood pressure of patients who have an uncontrolled ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program. The trial showed that anselamimab, a light chain depleter ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca's baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...